Select a medication above to begin.
Myfembree
relugolix/ estradiol/ norethindrone acetate
Black Box Warnings .
Thromboembolic Disorders and Vascular Events
estrogen + progestogen tx incr. thrombotic/thromboembolism risk including PE, DVT, stroke, and MI, especially patients at high risk for these events; contraindicated in patients with current or past history of thrombotic/thromboembolic disorder or if incr. risk, including smokers >35 yo and uncontrolled HTN
Adult Dosing .
Dosage forms: TAB: 40 mg/1 mg/0.5 mg
heavy menstrual bleeding, uterine fibroid-associated
- [1 tab PO qd]
- Start: after pregnancy excluded and within 7 days from onset of menses; Max: 24mo; Info: for premenopausal patients; D/C at least 4-6wk before major surgery if VTE risk
endometriosis-associated pain, moderate-severe
- [1 tab PO qd]
- Start: after pregnancy excluded and within 7 days from onset of menses; Max: 24mo; Info: for premenopausal patients; D/C at least 4-6wk before major surgery if VTE risk
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15 or ESRD: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- hepatic impairment/disease: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.